Preoperative Seizure Control and Perioperative Anesthetic Outcomes in Children Receiving Levetiracetam Versus

Anshika Agarwal1, Priyanka V Shah2, Parth S Shah3

  • 1Obstetrics and Gynaecology, Private Practice, Datia, IND.

Cureus
|May 11, 2026
PubMed

Insights

Levetiracetam and phenytoin show similar seizure prevention in children undergoing surgery. Levetiracetam offers faster recovery and shorter hospital stays, improving perioperative outcomes.

Area of Science:

  • Pediatric Anesthesiology
  • Epilepsy Management
  • Pharmacological Outcomes

Background:

  • Perioperative period increases seizure risk in pediatric epilepsy patients.
  • Phenytoin's IV loading linked to hemodynamic instability; oral therapy has fewer effects.
  • Levetiracetam offers favorable pharmacokinetics and fewer drug interactions.

Purpose of the Study:

  • Compare perioperative seizure incidence between levetiracetam and phenytoin in pediatric surgical patients.
  • Evaluate anesthetic outcomes, including complications and recovery.
  • Identify predictors of postoperative seizures.

Main Methods:

  • Prospective, comparative cohort study of 200 children (1-18 years) with epilepsy undergoing elective non-neurosurgical procedures.
  • 100 patients received levetiracetam monotherapy, 100 received phenytoin monotherapy, continued perioperatively.
  • Primary outcome: postoperative seizures within 24 hours; secondary outcomes: complications, recovery time, hospital stay.

Main Results:

  • Comparable postoperative seizure incidence (6% levetiracetam vs. 12% phenytoin, p=0.138) after adjustment.
  • Levetiracetam group showed significantly lower delayed emergence (7% vs. 19%, p=0.012).
  • Levetiracetam associated with shorter recovery time and hospital stay.

Conclusions:

  • Levetiracetam and phenytoin demonstrate similar efficacy in preventing postoperative seizures in pediatric surgical patients.
  • Levetiracetam offers advantages in perioperative recovery, including reduced delayed emergence and shorter hospital stays.
  • Pharmacological differences influence perioperative safety and recovery, favoring levetiracetam.

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...